IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: PRnewswire
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase 3 trial, significantly extending median overall survival by over five months compared to standard chemotherapy (13.6 months vs. 8.3 months), providing a new treatment option for advanced small cell lung cancer patients and marking a significant advancement in the treatment landscape.
- Regulatory Approval: The European Commission has approved IMDYLLTRA as a monotherapy for adults with advanced small cell lung cancer requiring systemic therapy, which not only offers new hope for patients but also reflects Amgen's commitment to innovative drug development, potentially improving patient survival rates significantly.
- Safety Profile Analysis: The safety profile of IMDYLLTRA was consistent with known characteristics, with the most common adverse reactions being cytokine release syndrome (56.7%) and decreased appetite (36.4%), necessitating strict monitoring during the initial treatment phase to ensure patient safety and treatment efficacy.
- Future Research Directions: Amgen's development program for IMDYLLTRA includes multiple clinical trials aimed at assessing its efficacy in various treatment stages, showcasing the company's robust research foundation in small cell lung cancer and providing more possibilities for future treatment regimens.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 328.260
Low
280.00
Averages
363.10
High
425.00
Current: 328.260
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen's IMDYLLTRA Approved for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in death risk in the DeLLphi-304 Phase 3 trial, with median overall survival increasing by over five months (13.6 months vs. 8.3 months), providing a new treatment option for small cell lung cancer patients and significantly improving survival expectations.
- Regulatory Approval: The European Commission approved IMDYLLTRA as a monotherapy for small cell lung cancer, marking it as the first T-cell therapy approved for this indication, reflecting Amgen's commitment to innovative drug development and expected to boost the company's market share in oncology.
- Safety Profile Analysis: The safety profile of IMDYLLTRA aligns with its known characteristics, with the most common adverse reactions being cytokine release syndrome (56.7%) and decreased appetite (36.4%), providing crucial safety data for clinical use and aiding physicians in treatment decisions.
- Future Research Directions: Amgen plans to continue clinical studies of IMDYLLTRA, including its use in combination with other therapies, aiming to further validate its efficacy in patients with small cell lung cancer at different stages, thereby enhancing its competitive position in the market.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase 3 trial, significantly extending median overall survival by over five months compared to standard chemotherapy (13.6 months vs. 8.3 months), providing a new treatment option for advanced small cell lung cancer patients and marking a significant advancement in the treatment landscape.
- Regulatory Approval: The European Commission has approved IMDYLLTRA as a monotherapy for adults with advanced small cell lung cancer requiring systemic therapy, which not only offers new hope for patients but also reflects Amgen's commitment to innovative drug development, potentially improving patient survival rates significantly.
- Safety Profile Analysis: The safety profile of IMDYLLTRA was consistent with known characteristics, with the most common adverse reactions being cytokine release syndrome (56.7%) and decreased appetite (36.4%), necessitating strict monitoring during the initial treatment phase to ensure patient safety and treatment efficacy.
- Future Research Directions: Amgen's development program for IMDYLLTRA includes multiple clinical trials aimed at assessing its efficacy in various treatment stages, showcasing the company's robust research foundation in small cell lung cancer and providing more possibilities for future treatment regimens.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase III trial, significantly improving patient survival compared to standard chemotherapy, indicating its potential in small cell lung cancer treatment.
- Market Access: The European Commission's approval of IMDYLLTRA as a monotherapy for small cell lung cancer patients fills a treatment gap in this area, expected to generate new revenue streams for Amgen and enhance its market competitiveness.
- Patient Benefits: The approval of IMDYLLTRA provides a new treatment option for patients whose disease progressed after chemotherapy, potentially improving their quality of life and survival, reflecting the urgent need for innovative therapies.
- Safety Profile: IMDYLLTRA's safety aligns with known side effects, with cytokine release syndrome among the adverse reactions, but its incidence remains manageable, ensuring patient safety during treatment.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: The global Phase III trial DeLLphi-304 demonstrated that IMDYLLTRA reduced the risk of death by 40% in small cell lung cancer patients and extended median overall survival by over five months, highlighting its potential in treatment.
- EU Approval: IMDYLLTRA received approval from the European Commission, becoming the first T-cell activator therapy for small cell lung cancer, marking a significant breakthrough in the field and expected to enhance treatment options and survival rates for patients.
- Safety Profile: The safety profile of IMDYLLTRA aligns with known characteristics, with common adverse reactions including cytokine release syndrome (56.7%) and decreased appetite (36.4%), indicating its acceptability in clinical use.
- Future Research Directions: The clinical development program for IMDYLLTRA includes multiple follow-up studies aimed at assessing its efficacy in different treatment stages, further advancing innovation in small cell lung cancer treatment.
See More
Amgen Presents New Data on UPLIZNA and TAVNEOS at EULAR 2026
- UPLIZNA Long-Term Safety: At the EULAR 2026 Congress, Amgen presented new data from the Phase 3 MITIGATE trial of UPLIZNA in IgG4-related disease, demonstrating its long-term safety and efficacy, which aids clinicians in identifying early intervention opportunities to reduce patient flare risks.
- Natural History of IgG4-RD: The natural history analysis from the MITIGATE trial revealed patterns of multi-organ involvement in IgG4-RD, underscoring the need for early intervention and comprehensive monitoring to improve long-term patient outcomes, reflecting Amgen's depth of research in this area.
- TAVNEOS Efficacy Evidence: New findings indicate that TAVNEOS effectively reduces steroid use in patients with ANCA-associated vasculitis, showing that patients can achieve disease control while decreasing reliance on glucocorticoids, highlighting its potential in treatment.
- Clinical Practice Impact: Amgen's research emphasizes the importance of reducing steroid use in treating rare autoimmune diseases, potentially offering patients safer treatment options, lowering long-term medication risks, and improving quality of life.
See More
Amgen Secures EU Approval for Antitumor Drug Imdelltra
- Drug Approval: Amgen's antitumor agent Imdelltra (tarlatamab) has received marketing authorization from the European Commission, providing a late-line treatment option for specific small cell lung cancer patients, marking a significant expansion in the company's oncology portfolio.
- Clinical Data Support: The approval is backed by data from the DeLLphi-304 Phase 3 trial, which demonstrated that Imdelltra reduced mortality risk by 40% compared to standard chemotherapy, significantly improving patient survival rates and enhancing its competitive position in the market.
- Market Timing: The EU approval for Imdelltra comes shortly after its full FDA approval in November, indicating Amgen's rapid global market positioning to meet the increasing demand for small cell lung cancer treatments.
- Strategic Implications: This approval not only opens a new revenue stream for Amgen but also reinforces its leadership in the biopharmaceutical sector, expected to drive future growth and innovation for the company.
See More
Amgen's IMDYLLTRA Approved for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in death risk in the DeLLphi-304 Phase 3 trial, with median overall survival increasing by over five months (13.6 months vs. 8.3 months), providing a new treatment option for small cell lung cancer patients and significantly improving survival expectations.
- Regulatory Approval: The European Commission approved IMDYLLTRA as a monotherapy for small cell lung cancer, marking it as the first T-cell therapy approved for this indication, reflecting Amgen's commitment to innovative drug development and expected to boost the company's market share in oncology.
- Safety Profile Analysis: The safety profile of IMDYLLTRA aligns with its known characteristics, with the most common adverse reactions being cytokine release syndrome (56.7%) and decreased appetite (36.4%), providing crucial safety data for clinical use and aiding physicians in treatment decisions.
- Future Research Directions: Amgen plans to continue clinical studies of IMDYLLTRA, including its use in combination with other therapies, aiming to further validate its efficacy in patients with small cell lung cancer at different stages, thereby enhancing its competitive position in the market.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase 3 trial, significantly extending median overall survival by over five months compared to standard chemotherapy (13.6 months vs. 8.3 months), providing a new treatment option for advanced small cell lung cancer patients and marking a significant advancement in the treatment landscape.
- Regulatory Approval: The European Commission has approved IMDYLLTRA as a monotherapy for adults with advanced small cell lung cancer requiring systemic therapy, which not only offers new hope for patients but also reflects Amgen's commitment to innovative drug development, potentially improving patient survival rates significantly.
- Safety Profile Analysis: The safety profile of IMDYLLTRA was consistent with known characteristics, with the most common adverse reactions being cytokine release syndrome (56.7%) and decreased appetite (36.4%), necessitating strict monitoring during the initial treatment phase to ensure patient safety and treatment efficacy.
- Future Research Directions: Amgen's development program for IMDYLLTRA includes multiple clinical trials aimed at assessing its efficacy in various treatment stages, showcasing the company's robust research foundation in small cell lung cancer and providing more possibilities for future treatment regimens.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: IMDYLLTRA demonstrated a 40% reduction in mortality risk in the DeLLphi-304 Phase III trial, significantly improving patient survival compared to standard chemotherapy, indicating its potential in small cell lung cancer treatment.
- Market Access: The European Commission's approval of IMDYLLTRA as a monotherapy for small cell lung cancer patients fills a treatment gap in this area, expected to generate new revenue streams for Amgen and enhance its market competitiveness.
- Patient Benefits: The approval of IMDYLLTRA provides a new treatment option for patients whose disease progressed after chemotherapy, potentially improving their quality of life and survival, reflecting the urgent need for innovative therapies.
- Safety Profile: IMDYLLTRA's safety aligns with known side effects, with cytokine release syndrome among the adverse reactions, but its incidence remains manageable, ensuring patient safety during treatment.
See More
IMDYLLTRA Approved by EU for Small Cell Lung Cancer Treatment
- Clinical Trial Results: The global Phase III trial DeLLphi-304 demonstrated that IMDYLLTRA reduced the risk of death by 40% in small cell lung cancer patients and extended median overall survival by over five months, highlighting its potential in treatment.
- EU Approval: IMDYLLTRA received approval from the European Commission, becoming the first T-cell activator therapy for small cell lung cancer, marking a significant breakthrough in the field and expected to enhance treatment options and survival rates for patients.
- Safety Profile: The safety profile of IMDYLLTRA aligns with known characteristics, with common adverse reactions including cytokine release syndrome (56.7%) and decreased appetite (36.4%), indicating its acceptability in clinical use.
- Future Research Directions: The clinical development program for IMDYLLTRA includes multiple follow-up studies aimed at assessing its efficacy in different treatment stages, further advancing innovation in small cell lung cancer treatment.
See More
Amgen Presents New Data on UPLIZNA and TAVNEOS at EULAR 2026
- UPLIZNA Long-Term Safety: At the EULAR 2026 Congress, Amgen presented new data from the Phase 3 MITIGATE trial of UPLIZNA in IgG4-related disease, demonstrating its long-term safety and efficacy, which aids clinicians in identifying early intervention opportunities to reduce patient flare risks.
- Natural History of IgG4-RD: The natural history analysis from the MITIGATE trial revealed patterns of multi-organ involvement in IgG4-RD, underscoring the need for early intervention and comprehensive monitoring to improve long-term patient outcomes, reflecting Amgen's depth of research in this area.
- TAVNEOS Efficacy Evidence: New findings indicate that TAVNEOS effectively reduces steroid use in patients with ANCA-associated vasculitis, showing that patients can achieve disease control while decreasing reliance on glucocorticoids, highlighting its potential in treatment.
- Clinical Practice Impact: Amgen's research emphasizes the importance of reducing steroid use in treating rare autoimmune diseases, potentially offering patients safer treatment options, lowering long-term medication risks, and improving quality of life.
See More
Amgen Secures EU Approval for Antitumor Drug Imdelltra
- Drug Approval: Amgen's antitumor agent Imdelltra (tarlatamab) has received marketing authorization from the European Commission, providing a late-line treatment option for specific small cell lung cancer patients, marking a significant expansion in the company's oncology portfolio.
- Clinical Data Support: The approval is backed by data from the DeLLphi-304 Phase 3 trial, which demonstrated that Imdelltra reduced mortality risk by 40% compared to standard chemotherapy, significantly improving patient survival rates and enhancing its competitive position in the market.
- Market Timing: The EU approval for Imdelltra comes shortly after its full FDA approval in November, indicating Amgen's rapid global market positioning to meet the increasing demand for small cell lung cancer treatments.
- Strategic Implications: This approval not only opens a new revenue stream for Amgen but also reinforces its leadership in the biopharmaceutical sector, expected to drive future growth and innovation for the company.
See More
